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Background  Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at 
increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is 
unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with inci-
dent HF/CM. 
  Methods  We conducted a population-based, retrospective cohort study of 12 500 women diagnosed with incident, invasive 
breast cancer from January 1, 1999 through December 31, 2007, at eight integrated Cancer Research Network health 
systems. Using administrative procedure and pharmacy codes, we identified anthracycline, trastuzumab, and other 
chemotherapy use. We identified incident HF/CM following chemotherapy initiation and assessed risk of HF/CM 
with time-varying chemotherapy exposures vs no chemotherapy. Multivariable Cox proportional hazards regres-
sion models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with adjustment for age 
at diagnosis, stage, Cancer Research Network site, year of diagnosis, radiation therapy, and comorbidities.  
  Results  Among 12 500 women (mean age = 60 years, range = 22–99 years), 29.6% received anthracycline alone, 0.9% 
received trastuzumab alone, 3.5% received anthracycline plus trastuzumab, 19.5% received other chemother-
apy, and 46.5% received no chemotherapy. Anthracycline and trastuzumab recipients were younger, with fewer 
comorbidities than recipients of other chemotherapy or none. Compared with no chemotherapy, the risk of HF/
CM was higher in patients treated with anthracycline alone (adjusted HR = 1.40, 95% CI = 1.11 to 1.76), although the 
increased risk was similar to other chemotherapy (adjusted HR = 1.49, 95% CI = 1.25 to 1.77); the risk was highly 
increased in patients treated with trastuzumab alone (adjusted HR = 4.12, 95% CI = 2.30 to 7.42) or anthracycline 
plus trastuzumab (adjusted HR = 7.19, 95% CI = 5.00 to 10.35). 
Conclusions  Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased 
HF/CM risk compared with no chemotherapy. This population-based observational study complements findings 
from clinical trials on cancer treatment safety.
    J Natl Cancer Inst 2012;104:1293–1305
Breast cancer is one of the most common cancers in the United 
States with an estimated 232  620 new diagnoses in 2011 (1). 
Chemotherapeutic regimens for invasive breast cancer in women 
include neoadjuvant or adjuvant anthracycline in combination with 
cyclophosphamide (2). A major advance in breast cancer treatment 
has been the incorporation of trastuzumab, a monoclonal anti-
body against HER2/neu. Approximately 20%–25% of women with 
breast cancer overexpress HER2 and are recommended for trastu-
zumab therapy following the completion of anthracycline therapy 
(3–5). Randomized clinical trials have demonstrated that these reg-
imens are highly effective in improving disease-free survival (6–9); 
however, side effects are not minimal.
Data from clinical trials indicate that anthracycline use is asso-
ciated with an approximate 2% increase (10–14) in heart failure 
and/or cardiomyopathy (HF/CM) incidence, and anthracycline 
followed by trastuzumab is associated with an approximate 4% 
increase (15–19). Clinical trial findings were critical in leading to 
prescribing warnings and protocols for regular cardiac function 
monitoring before and during treatment (20–22). However, trials 
typically exclude older women (eg, aged ≥ 70 years) and women 
with major comorbidities; therefore, the association between 
anthracycline and/or trastuzumab use and HF/CM in this popula-
tion is not well understood. The effectiveness of these treatments 
and risk of cardiotoxicity may differ in community practice. Three Vol. 104, Issue 17  |  September 5, 2012 1294 Articles | JNCI
observational studies using Surveillance, Epidemiology, and End 
Results (SEER) Medicare data have evaluated HF/CM incidence 
following treatment with anthracycline, but they were limited to 
older women (aged ≥ 65 years) and did not evaluate trastuzumab 
(23–25). Therefore, broader population-based estimates of HF/CM 
risk associated with anthracycline and trastuzumab are unknown.
Using data from the health maintenance organization (HMO) 
Cancer Research Network (CRN) (26), we evaluated real-world 
adjuvant anthracycline and trastuzumab use and subsequent inci-
dent HF/CM risk among a population-based cohort of women 
aged 18 years or older and diagnosed with invasive breast cancer. 
We took advantage of observational administrative health plan 
data to conduct this comparative safety study of anthracycline 
therapy, which was previously examined only in clinical trials or 
SEER-Medicare populations, and trastuzumab therapy, which, 
to our knowledge, has not been evaluated outside of randomized 
clinical trials.
Methods
Study Population
The CRN is a consortium of 14 nonprofit research centers based 
in integrated healthcare delivery organizations within the HMO 
Research Network (26). We included 12 902 women aged 18 years 
or older and diagnosed with incident invasive [SEER summary 
stages—local, which is confined to the breast, or regional, which 
has spread to the lymph nodes (27)] breast cancer from January 1, 
1999 through December 31, 2007. All women were enrolled at least 
12 months before diagnosis in these six CRN sites: Group Health 
Cooperative, Henry Ford Hospital and Health System, Marshfield 
Clinic, and Kaiser Permanente regions in Colorado, Georgia, 
and Northwest. Two additional CRN sites (Kaiser Permanente 
Northern California and Harvard Pilgrim Health Care) used 
slightly different inclusion criteria for year of breast cancer diagno-
sis. Because of the large population at Kaiser Permanente Northern 
California, we included a 10% random sample of women diagnosed 
between January 1, 2001 and December 31, 2007 (chemotherapy 
data from 1999 and 2000 were incomplete and not included). 
Harvard Pilgrim data included women receiving care at Harvard 
Vanguard Medical Associates (a multispecialty medical practice) 
and diagnosed from January 1, 1999 through December 31, 2006.
We excluded women diagnosed with HF/CM before breast 
cancer diagnosis (n = 253 women) or before chemotherapy initia-
tion (n = 96 women) because these diagnoses could not be attrib-
uted to chemotherapy use. We also excluded women who did not 
receive chemotherapy but were diagnosed with HF/CM within 
70 days of breast cancer diagnosis (70 days was the median time 
to “other chemotherapy” initiation; n = 53 women). These women 
may have been eligible for chemotherapy but likely did not receive 
it because of their new HF/CM diagnosis (potentially found dur-
ing cardiac screening before the anticipated chemotherapy initia-
tion). In general, excluded HF/CM patients were older (55% were 
>75 years) and had more comorbidities (70.8% had a Charlson 
comorbidity score ≥ 2 [moderate comorbidity]), compared with 
our included cohort (18% were >75 years and 15% had a Charlson 
comorbidity score ≥ 2). Over 50% of excluded HF/CM patients 
did not receive any chemotherapy, although 10% of these women 
received anthracycline and/or trastuzumab. Our final analytic sam-
ple included 12 500 women. Women were followed-up until inci-
dent HF/CM diagnosis, health plan disenrollment, death, or the 
end of follow-up on December 31, 2009, whichever came first.
This study was approved by the Institutional Review Board 
(IRB) for Group Health Cooperative and five other sites that 
ceded review to Group Health Cooperative and separately by the 
Institutional Review Boards at Marshfield Clinic and Henry Ford. 
We obtained information on women from all sites via a waiver of 
consent.
Data Collection
We obtained data from each site’s Virtual Data Warehouse 
(VDW), which has been described in detail elsewhere (28). The 
VDW includes standardized variables derived from administra-
tive databases at each CRN site. A programmer at Group Health 
Cooperative wrote standardized code for programmers at other 
sites to execute; programmers then transferred limited datasets to 
Group Health Cooperative for analysis.
Chemotherapy Exposure
We collected data on chemotherapy administration using vali-
dated VDW procedure codes and pharmacy data, which have been 
reported previously (29). Chemotherapy procedure data included 
Healthcare Common Procedure Coding System (HCPCS) 
and Current Procedural Terminology (CPT)-4 codes; phar-
macy data included National Drug Codes (NDCs). We extracted 
HCPCS and NDCs specific to anthracycline and trastuzumab and 
HCPCS, NDCs, and CPT-4 codes related to other chemother-
apy and administration dates. Because CPT-4 codes do not spe-
cify chemotherapy agents, we coded CPT-4 codes with no other 
information as “other” chemotherapy. We extracted treatment 
data up to 24 months after breast cancer diagnosis. We catego-
rized women into five mutually exclusive treatment categories: 
anthracycline-based only (without trastuzumab; however, women 
could have received additional chemotherapy such as cyclophos-
phamide), trastuzumab-based only (without anthracycline; though 
all but one woman received additional chemotherapy), anthracy-
cline plus trastuzumab (trastuzumab therapy following anthracy-
cline therapy), other chemotherapy, or no chemotherapy.
To validate chemotherapy data, we compared chemotherapy 
regimens from VDW data with medical record review of 400 
women (50 from each CRN site). Sensitivities and specificities 
exceeded 90% for all treatment categories, and positive predictive 
values (PPVs) exceeded 90% for anthracycline alone, trastuzumab 
alone, and anthracycline plus trastuzumab treatment, as reported 
previously (29).
Heart Failure Outcome
Our primary outcome was HF/CM following breast cancer diag-
nosis, defined using a previously validated algorithm, though not 
in breast cancer patients (30). The algorithm uses International 
Classification of Diseases, Ninth Revision (ICD-9) codes with five 
different criteria that indicate HF/CM (see Table 1 for   criteria, 
ICD-9 codes, and proportion of women classified by each   criteria) 
(31). We categorized women as having no HF/CM or incident 
HF/CM (occurring after breast cancer treatment). Because JNCI | Articles 1295 jnci.oxfordjournals.org
administrative data do not capture results of echocardiograms 
or other methods for measuring left ventricular ejection fraction 
(LVEF), we could not use LVEF findings in our HF/CM defin-
ition. The PPV of the algorithm for any HF/CM diagnosis during 
the period from 12 months before to 12 months after breast can-
cer diagnosis was 68.6% (95% confidence interval [CI] = 44.9% to 
85.4%), which we have shown earlier (31). The PPV for incident 
HF/CM during the 12 months after breast cancer diagnosis was 
33.3% (95% CI = 12.8% to 63.1%) (31); this estimate was based 
on only four true-positive HF/CM patients, but it suggests that 
the performance may be worse for the period after breast cancer 
diagnosis. PPV also varied by the definition of the gold standard, 
and the estimates above included 24 “indeterminate” diagnoses 
(those that could not be definitively classified as HF/CM) as nega-
tives in the gold standard. When we included patients with “inde-
terminate” HF/CM diagnoses as positives in the gold standard, 
the PPV of the algorithm increased to 81.9% (95% CI = 58.0% 
to 93.7%), as reported previously (31). We did not have gold 
standard data to evaluate the PPV for incident heart failure after 
chemotherapy initiation or beyond 12 months after breast cancer 
diagnosis.
Covariates
Each CRN site maintains its own tumor registry in compliance 
with North American Association of Central Cancer Registries 
(NAACCR) standards, or contracts with their local state or SEER 
tumor registries. From tumor registry data, we collected data on 
breast cancer diagnosis date, age at diagnosis (<55, 55–64, 65–74, 
≥75 years), race (American Indian or Alaskan Native, Asian, black, 
white), ethnicity (non-Hispanic white vs Hispanic), summary stage 
(localized vs regional), lymph node status (positive vs negative), and 
radiation therapy (yes vs no) as defined by NAACCR classifica-
tions. Using VDW data, we calculated the Charlson comorbid-
ity index (0, 1, 2, ≥3) that weights up to 19 comorbid conditions 
depending on their seriousness, using the Deyo index based on the 
presence of relevant ICD-9 codes in the year before breast cancer 
diagnosis (32,33).
Statistical Analysis
We described the distribution of chemotherapy use by patient 
characteristics, including the median and interquartile range 
(25th–75th percentile) for follow-up time (time for follow-up 
treatment until incident HF/CM diagnosis, health plan 
disenrollment, death, or December 31, 2009, whichever came first). 
We then used Cox proportional hazards regression to calculate 
hazard ratios (HRs) with 95% (CIs) for HF/CM associated with 
time-varying chemotherapy exposures. Each participant began 
accruing person-time on the date of chemotherapy initiation (ie, 
index date) and stopped accruing person-time at the time of incident 
HF/CM diagnosis, health plan disenrollment, death, or December 
31, 2009, whichever came first. We used day 70 after diagnosis as a 
proxy for the index date for unexposed women. Using time-varying 
exposures allowed us to account for changes in chemotherapy use. 
For example, women were considered anthracycline-based-only 
users until they started trastuzumab therapy; thereafter, they were 
considered anthracycline plus trastuzumab users. We adjusted 
all models for covariates that were either jointly associated with 
chemotherapy and HF/CM risk (confounders) or associated solely 
with HF/CM risk in a bivariate manner at P values less than .05. 
These included CRN site (eight sites mentioned earlier), age at 
diagnosis (grouped as <55, 55–64, 65–74, ≥75  years), Charlson 
comorbidity index (0, 1, 2, ≥3), summary stage at diagnosis 
(localized vs regional), year of diagnosis (categorical for each year), 
and radiation treatment (yes vs no).
Survivor curves and the corresponding cumulative incidence 
curves were estimated from the adjusted Cox model using the 
method described by Breslow (34,35). All covariates were set to 
their respective mean values as estimated from the overall sample. 
The annual cumulative incidence up to year 5 for each chemother-
apy group, both overall and by age group, was estimated at the most 
proximal event time observed in the data. Numbers of patients at 
risk are presented as the number under observation at the begin-
ning of each time interval.
In order to assess any violations to the proportional hazards 
assumption in our primary analysis (average hazards ratios for 
Table 1.  ICD-9 code-based algorithm used to determine HF/CM from administrative data by treatment group*
Treatment group
No 
chemotherapy
Anthracycline 
only
Trastuzumab 
only
Anthracycline + 
trastuzumab
Other 
chemotherapy
(n=5807 women) (n=3697 women) (n=112 women) (n=442 women) (n=2442 women)
Algorithm criteria % % % % %
≥1 primary discharge diagnosis 4.2 2.1 3.6 4.1 5.3
≥3 secondary discharge diagnoses 0.5 0.2 0 0.5 0.4
≥2 outpatient diagnoses 2.8 1.7 7. 1 7. 0 2.5
≥3 emergency department diagnoses 0 0 0 0 0
≥2 secondary discharge + ≥1 outpatient diagnosis 0.1 0.1 0 0 0.2
None of the above (no HF/CM) 92.5 95.9 89.3 88.5 91.7
*    The study population includes 12 500 women diagnosed with incident invasive breast cancer from January 1, 1999 through December 31, 2007 . All women were 
members of one of eight Cancer Research Network (CRN) integrated health plans for 12 or more months before breast cancer diagnosis. Administrative data 
included ICD-9 codes for HF/CM as noted by a provider in the medical record and available in the CRN Virtual Data Warehouse (VDW; ICD-9 codes: 398.91, 402.
x1, 402.x3, 404.x1, 404.x3, 422.90, 425.4, 425.9, 428.xx). Primary and secondary discharge diagnoses were indicated at the time of the patient’s release from 
a hospital. Other diagnoses occurred after emergency department release or an outpatient appointment. The algorithm for this study was based on previous HF 
claims-based algorithms (30,41), with the addition of the 425 “cardiomyopathy” codes because of the nature of cardiotoxicity. The algorithm was validated on a 
subset of 400 women as previously reported (31). ICD-9 = International Classification of Diseases, Ninth Revision; HF/CM = Heart failure and/or cardiomyopathy.Vol. 104, Issue 17  |  September 5, 2012 1296 Articles | JNCI
chemotherapy exposure during the entire study period), we per-
formed exploratory analyses to characterize changes of the hazard 
ratio over time for each chemotherapy exposure. Toward this end, 
we allowed the hazard ratio for each chemotherapy exposure to 
vary with time by including an interaction with time in our models. 
The degree to which the proportional hazards assumption was vio-
lated for covariates was assessed through the use of the likelihood 
ratio test for interactions between covariates and time, as well as 
inspection of residual plots. Interactions with time were statistically 
significant at P values less than .05 for age, stage, site, Charlson 
score, and year of diagnosis. Review of residual plots yielded very 
little in the way of substantial proportional hazards violations, and 
most were focused in areas of sparse data. We conducted sensi-
tivity analyses with stratified models when there was evidence of 
a potential deviation from the proportional hazards assumption. 
Sensitivity analyses yielded minimal changes in primary estimates; 
thus, we present results based on the primary, unstratified analysis.
We conducted several sensitivity analyses in order to address 
potential limitations and biases in observational administrative 
data. We conducted Cox regression analyses after changing the 
proxy index date to 234 days after breast cancer diagnosis (the 75th 
percentile of time to “other chemotherapy” initiation) in unex-
posed women; excluding women with comorbidities (Charlson 
score >1; n = 1854 women); excluding women who initiated ther-
apy more than 12 months after breast cancer diagnosis (n = 519 
women); and excluding women diagnosed before 2004 (when there 
was limited use of trastuzumab in the adjuvant setting; n = 6779 
women). Further, we conducted stratified analyses by CRN site and 
age group.
The majority of analyses were conducted in Stata 11 (StataCorp, 
College Station, TX); cumulative incidence estimates were 
estimated with SAS version 9.2 for Windows (SAS Institute Inc, 
Cary, NC). All hypothesis tests were two-sided, and we considered 
P values less than .05 statistically significant.
results
Characteristics of Patients by Chemotherapy Use
Among 12 500 women who were diagnosed with invasive breast 
cancer from January 1, 1999 through December 31, 2007, chemo-
therapy use was as follows: 5807 (46.5%) received no chemother-
apy, 3697 (29.6%) received anthracycline-based chemotherapy 
alone, 112 (0.9%) received trastuzumab-based therapy without 
anthracycline, 442 (3.5%) received anthracycline plus trastuzumab, 
and 2442 (19.5%) received other chemotherapy (Table  2). The 
mean age of the population was 60 years (range = 22–99 years), 
85.8% were of white race, and the median follow-up time was 
4.4 years (interquartile range [IQR] = 2.6–6.9 years). Women who 
received anthracycline alone or anthracycline plus trastuzumab 
were younger (age <65  years, 86.4% and 89.6%, respectively), 
diagnosed at later stages (regional SEER summary stage, 54.2% 
and 61.0%, respectively), had fewer comorbidities (Charlson score 
≥2, 10.0% and 7.7%, respectively), and were slightly more likely to 
receive radiation therapy (yes, 61.0% and 59.4%, respectively) than 
women who received other chemotherapy (age <65 years, 54.2%; 
SEER regional summary stage, 25.4%; Charlson score ≥2, 19.8%; 
and radiation therapy received, 55.2%) or no chemotherapy (age   
<65 years, 55.3%; regional summary stage, 11.5%; Charlson score 
≥2, 16.2%; and radiation therapy received, 58.6%). Recipients of 
trastuzumab-based therapy without anthracycline, though small 
in number, were older (age ≥65  years, 32.2%) and had more 
comorbidities (Charlson score ≥2, 21.4%) than women in other 
treatment groups.
Risk of HF/CM by Chemotherapy Exposure
Women were followed-up until incident HF/CM diagnosis, health 
plan disenrollment, death, or December 31, 2009, whichever came 
first. The adjusted cumulative HF/CM incidence for the first 
5 years of follow-up (the median follow-up time was 4.4 years) is 
shown in Figure 1. The HF/CM incidence among anthracycline 
recipients increased with increasing follow-up time (year 1 vs year 
5, cumulative incidence = 1.2% [95% CI = 1.0% to 1.5%] vs 4.3% 
[95% CI = 3.5% to 5.0%]) and was similar to the incidence among 
recipients of other chemotherapy (year 1 vs year 5, cumulative inci-
dence = 1.3% [95% CI = 1.0% to 1.6%] vs 4.5% [95% CI = 3.7% 
to 5.3%]). The cumulative HF/CM incidence among recipients 
of anthracycline plus trastuzumab was 6.2% (95% CI = 4.1% to 
8.2%) after 1 year of follow-up and continued to increase to 20.1% 
(95% CI = 14.0% to 25.6%) by 5 years. The risk of incident HF/
CM among all women was statistically significantly increased for 
anthracycline alone (adjusted HR = 1.40, 95% CI = 1.11 to 1.76), 
trastuzumab without anthracycline (HR = 4.12, 95% CI = 2.30 to 
7.42), anthracycline plus trastuzumab (HR = 7.19, 95% CI = 5.00 
to 10.35), and other chemotherapy (HR = 1.49, 95% CI = 1.25 to 
1.77), compared with no chemotherapy (Table 3).
Risk of HF/CM by Age at Breast Cancer Diagnosis
The 5-year cumulative incidence for HF/CM associated with 
anthracycline use increased with increasing age (among age 
<55  years, cumulative incidence  =  1.2% [95% CI  =  0.0% to 
26.1%]; among age 55–64  years, cumulative incidence =2.9% 
[95% CI = 1.8% to 4.0%]; among age 65–74 years, cumulative inci-
dence = 6.2% [95% CI = 3.9% to 8.5%]; and among age ≥75 years, 
cumulative incidence  =  10.6% [95% CI  =  3.9% to 16.9%]; 
Figure 2, A–D). The 5-year cumulative incidence for HF/CM asso-
ciated with anthracycline plus trastuzumab use also increased with 
increasing age (among age <55 years, cumulative incidence = 7.5% 
[95% CI  =  0.0% to 85.9%]; among age 55–64  years, cumula-
tive incidence = 11.4% [95% CI = 4.2% to 18.1%]; among age 
65–74 years, cumulative incidence = 35.6% [95% CI = 12.5% to 
52.5%]; and among age ≥75 years, cumulative incidence = 40.7% 
[95% CI = 0.0% to 71.6%]; Figure 2, A–D). The 5-year cumula-
tive incidences for HF/CM associated with other chemotherapy 
use were greatest among the two oldest age groups (among age 
65–74  years, cumulative incidence  =  8.7% [95% CI  =  6.3% to 
11.0%] and among age ≥75 years, cumulative incidence = 18.7% 
[95% CI = 14.5% to 22.6%]; Figure 2, C and D).
The hazard ratios for HF/CM associated with chemotherapy use 
decreased with increasing age (Table 3). For example, the hazard 
ratio for HF/CM associated with anthracycline use alone was statis-
tically significant among women younger than 55 years (HR = 2.52, 
95% CI  =  1.20 to 5.29) but not among women 55–64  years 
(HR = 1.61, 95% CI = 0.94 to 2.78) or older. The hazard ratios for 
incident HF/CM associated with anthracycline plus trastuzumab JNCI | Articles 1297 jnci.oxfordjournals.org
use were statistically significant among the three younger age 
groups (among age <55 years, HR = 16.36 [95% CI = 6.59 to 40.65]; 
among age 55–64 years, HR = 6.69 [95% CI = 3.09 to 14.48]; and 
among age 65–74 years, HR = 8.34 [95% CI = 3.97 to 17.50]). The 
hazard ratios for HF/CM associated with other chemotherapy 
use were statistically significant among the three older age groups 
(among age 55–64 years, HR = 1.82 [95% CI = 1.03 to 3.20]; among 
age 65–74 years, HR = 1.73 [95% CI = 1.28 to 2.34]; and among age 
≥75 years, HR = 1.40 [95% CI = 1.11 to 1.78]).
Sensitivity Analyses
We also conducted several sensitivity analyses to address poten-
tial limitations and biases in observational administrative data. 
No appreciable differences with primary analysis were obtained 
(Table 3). In general, stronger associations between chemother-
apy exposure and incident HF/CM were observed on changing 
the index date of unexposed women (n = 12 500), and excluding 
women with higher comorbidity scores (n = 10 646), or women 
who initiated chemotherapy more than 12 months after diagnosis 
(n = 11 981). Excluding women diagnosed before 2004 or stratify-
ing by CRN site did not greatly alter results, though confidence 
intervals were much wider because of the smaller sample size (data 
not shown).
Discussion
This study had two goals: 1) to describe real-world adjuvant anthra-
cycline and trastuzumab use and 2) to evaluate incident HF/CM 
Table 2.  Characteristics of invasive breast cancer patients by adjuvant treatment*
Treatment group
No chemo-
therapy (n=5807 
women)
Anthracycline 
only (n=3697 
women)
Trastuzumab 
only (n=112 
women)
Anthracycline 
+ trastuzumab 
(n=442 women)
Other chemo-
therapy (n=2442 
women)
All (n=12500 
women)
Characteristic No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Age at diagnosis, y
 <55 1112 (19.1) 2131 (57 .6) 40 (35.7) 272 (61.5) 706 (28.9) 4261 (34.1)
 55–64 1489 (25.6) 1063 (28.8) 36 (32.1) 124 (28.1) 617 (25.3) 3329 (26.6)
 65–74 1606 (27 .7) 423 (11.4) 19 (17 .0) 38 (8.6) 622 (25.5) 2708 (21.7)
 ≥75 1600 (27 .6) 80 (2.2) 17 (15.2) 8 (1.8) 497 (20.4) 2202 (17 .6)
Race
  American Indian or Alaskan Native 9 (0.2) 11 (0.3) 0 (0.0 0  4 (0.9) 11 (0.5) 35 (0.3)
 Asian 203 (3.6) 149 (4.1) 4 (3.6) 27 (6.2) 94 (3.9) 477 (3.9)
 Black 443 (7 .8) 527 (14.5) 16 (14.5) 51 (11.8) 193 (8.0) 1230 (10.0)
 White 5016 (88.5) 2952 (81.1) 90 (81.8) 352 (81.1) 2103 (87 .6) 10 513 (85.8)
Ethnicity
 Non-Hispanic 5165 (97 .5) 3310 (95.9) 95 (96.0) 386 (95.1) 2237 (96.8) 11 193 (96.8)
 Hispanic 133 (2.5) 141 (4.1) 4 (4.0) 20 (4.9) 75 (3.2) 373 (3.2)
Summary stage†
 Localized 5066 (88.5) 1683 (45.8) 67 (60.9) 171 (39.0) 1797 (74.6) 8784 (71.1)
 Regional 660 (11.5) 1991 (54.2) 43 (39.1) 268 (61.0) 612 (25.4) 3574 (28.9)
Lymph nodes
 Negative 5181 (89.2) 1654 (44.7) 72 (64.3) 164 (37 .1) 1843 (75.5) 8914 (71.3)
 Positive 626 (10.8) 2043 (55.3) 40 (35.7) 278 (62.9) 599 (24.5) 3586 (28.7)
Charlson score‡
 0 3983 (68.6) 2897 (78.4) 67 (59.8) 350 (79.2) 1567 (64.2) 8864 (70.9)
 1 881 (15.2) 430 (11.6) 21 (18.8) 58 (13.1) 392 (16.1) 1782 (14.3)
 2 635 (10.9) 284 (7 .7) 13 (11.6) 26 (5.9) 303 (12.4) 1261 (10.1)
 ≥3 308 (5.3) 86 (2.3) 11 (9.8) 8 (1.8) 180 (7 .4) 593 (4.7)
Radiation therapy
 No 2355 (41.4) 1397 (39.0) 58 (54.2) 174 (40.6) 1067 (44.8) 5051 (41.5)
 Yes 3331 (58.6) 2182 (61.0) 49 (45.8) 255 (59.4) 1317 (55.2) 7134 (58.5)
Diagnosis year
 1999–2003 3229 (55.6) 2054 (55.6) 26 (23.2) 94 (21.3) 1376 (56.3) 6779 (54.2)
 2004–2007 2578 (44.4) 1643 (44.4) 86 (76.8) 348 (78.7) 1066 (43.7) 5721 (45.8)
*    Women were diagnosed with breast cancer between January 1, 1999 and December 31, 2007 . Chemotherapy use was extracted from the Cancer Research 
Network (CRN) Virtual Data Warehouse (VDW) procedure and pharmacy data up to 24 months after breast cancer diagnosis. Chemotherapy procedure data 
included Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT)-4 codes; pharmacy data included National Drug Codes 
(NDCs). “Anthracycline only” indicates treatment without trastuzumab, although women could have received additional chemotherapy such as cyclophosphamide. 
“Trastuzumab only” indicates treatment without anthracycline, although all but one woman received additional chemotherapy. “Anthracycline + trastuzumab” 
indicates trastuzumab therapy following anthracycline therapy. “Other chemotherapy” indicates CPT-4 codes without any information about specific chemotherapy 
agents, or HCPCS and NDCs that specified chemotherapy drugs other than anthracycline or trastuzumab. Diagnosis year was categorized as 1999–2003 and 
2004–2007 because there was little trastuzumab use in the adjuvant setting before 2004.
†    Surveillance, Epidemiology, and End Results (SEER) summary stages: local, which is confined to the breast, or regional, which has spread to the lymph nodes (27).
‡    Charlson comorbidity index, which weights up to 19 comorbid conditions depending on their seriousness, using the Deyo index based on the presence of relevant 
International Classification of Diseases, Ninth Revision (ICD-9) codes in the year before breast cancer diagnosis (32,33). We categorized the score as 0, 1, 2, and 
≥3, which represent an increasing scale of comorbid conditions but do not equate to a specific number of comorbid conditions.Vol. 104, Issue 17  |  September 5, 2012 1298 Articles | JNCI
risk associated with adjuvant anthracycline and/or trastuzumab 
use in a population-based cohort of women with breast cancer. In 
our study, women who received anthracycline alone or anthracy-
cline plus trastuzumab were younger and had fewer comorbidities 
than women who received other chemotherapy or no chemother-
apy. These results suggest substantial individualization of adjuvant 
chemotherapy administration by age and comorbidity in commu-
nity practice. The overall risk of incident HF/CM was statistic-
ally significantly increased among women who used anthracycline 
alone compared with no chemotherapy, but the overall risk of inci-
dent HF/CM was even greater among women who used trastu-
zumab. Compared with women who received no chemotherapy, 
our hazard ratios suggest a fourfold increase in the risk of HF/CM 
among women who received trastuzumab alone and a sevenfold 
increase in the risk of HF/CM for those who received anthracy-
cline plus trastuzumab. To our knowledge, this study is the first 
to examine associations between anthracycline and/or trastuzumab 
reception and HF/CM in a cohort of breast cancer patients broader 
than Medicare-eligible women or clinical trial participants.
Consistent with previous studies, the majority of women 
65  years or older in our population received no chemotherapy 
(36). Among older women who did receive chemotherapy, most 
received agents other than anthracycline or trastuzumab. Women 
who received anthracycline alone or with trastuzumab tended to 
have lower comorbidity prevalence, based on Charlson score. On 
the other hand, the small group of women (0.9%) who received 
Figure 1.  Cumulative incidence of heart failure and/or cardiomyopathy (HF/CM) in women with invasive breast cancer over 5 years by adjuvant 
chemotherapy group. Adjusted cumulative incidence of HF/CM and number of patients at risk by exposure group (anthracycline only, trastuzumab 
only, anthracycline + trastuzumab, other chemotherapy, or none) for the first 5 years of follow-up. Cumulative incidence was adjusted for Cancer 
Research Network (CRN) site (eight sites), age at diagnosis (<55, 55–64, 65–74, ≥75 years), Charlson comorbidity index (0, 1, 2, ≥3), summary stage 
at diagnosis (local vs regional), year of diagnosis (categorical for each year), and radiation treatment (yes vs no).JNCI | Articles 1299 jnci.oxfordjournals.org
trastuzumab alone had the highest prevalence of comorbidities. 
These findings show that typical clinical trial exclusions based on 
patients’ age and comorbidities do occur in real-world settings 
but to a lesser extent than in clinical trials (37–39). This treatment 
selection bias, especially by age, may alter cardiac risk estimates and 
safety profiles of these drugs in community settings.
Our results for HF/CM risk among women less than 65 years 
who received anthracycline alone were similar to clinical trial 
results (10–14). However, the risk of HF/CM among women who 
received trastuzumab with or without anthracycline in our study—
especially among younger women—was unexpectedly higher 
than clinical trial estimates (15–19). Excluding women with more 
comorbidities did not substantially change our results. The high 
hazard ratios associated with anthracycline plus trastuzumab may 
partially stem from detection bias, as young women receiving these 
treatments are much more likely to be monitored for cardiac fail-
ure than young women receiving no chemotherapy. These results 
suggest that clinical trials may underestimate the magnitude of 
HF/CM risk following anthracycline plus trastuzumab use in com-
munity practice.
Our results for older women showed little to no increase in 
HF/CM risk among anthracycline-alone users compared with 
women who received no chemotherapy. This finding conflicts 
with SEER-Medicare studies, which have estimated statistically 
significant hazard ratios ranging from 1.2 to 2.5 (23–25). This 
discrepancy is likely a result of avoidance of anthracycline-based 
therapy in older women; only 11.2% of women 65 years or older in 
our study were prescribed anthracycline. Earlier SEER-Medicare 
studies included only data from the 1990s; our study of more 
recent years likely reflects more careful treatment dosing, the 
Table 3.   Associations between adjuvant chemotherapy exposure and incident HF/CM among women diagnosed with invasive breast 
cancer*
Primary analysis Sensitivity analyses
All women  
(n=12 500)
Changing index date in 
unexposed† (n=12 500)
Excluding women with 
comorbidities‡ (n=10 646)
Excluding late chemother-
apy initiators§ (n=11 981)
Chemotherapy use Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI)
All ages
  No chemotherapy 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
  Anthracycline only 1.40 (1.11 to 1.76) 1.43 (1.13 to 1.81) 1.52 (1.18 to 1.97) 1.40 (1.11 to 1.77)
  Trastuzumab only 4.12 (2.30 to 7 .42) 4.33 (2.41 to 7 .80) 4.36 (2.21 to 8.58) 5.26 (2.91 to 9.50)
  Anthracycline + trastuzumab 7 .19 (5.00 to 10.35) 7 .35 (5.09 to 10.62) 7 .94 (5.36 to 11.76) 7 .19 (4.84 to 10.68)
  Other chemotherapy  1.49 (1.25 to 1.77) 1.53 (1.29 to 1.83) 1.33 (1.16 to 1.76) 1.44 (1.19 to 1.73)
Age <55 y
  No chemotherapy  1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
  Anthracycline only 2.52 (1.20 to 5.29) 2.65 (1.22 to 5.76) 3.42 (1.42 to 8.24) 2.49 (1.18 to 5.23)
  Trastuzumab only 15.46 (4.51 to 52.96) 16.20 (4.62 to 56.77) 15.90 (3.79 to 66.66) 17 .60 (5.09 to 60.86)
  Anthracycline + trastuzumab 16.36 (6.59 to 40.65) 16.96 (6.62 to 43.46) 18.26 (6.39 to 52.18) 17 .31 (6.70 to 44.74)
  Other chemotherapy 1.85 (0.77 to 4.45) 1.95 (0.78 to 4.83) 2.69 (0.98 to 7 .37) 1.81 (0.74 to 4.44)
Age 55–64 y
  No chemotherapy  1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
  Anthracycline only 1.61 (0.94 to 2.78) 1.56 (0.90 to 2.71) 1.75 (0.94 to 3.28) 1.61 (0.93 to 2.81)
  Trastuzumab only 10.76 (3.92 to 29.52) 10.19 (3.69 to 28.10) 14.88 (4.66 to 47 .53) 11.81 (4.28 to 32.59)
  Anthracycline + trastuzumab 6.69 (3.09 to 14.48) 6.40 (2.94 to 13.94) 10.79 (4.70 to 24.77) 6.05 (2.66 to 13.77)
  Other chemotherapy 1.82 (1.03 to 3.20) 1.75 (0.99 to 3.10) 1.77 (0.91 to 3.44) 1.77 (0.98 to 3.19)
Age 65–74 y
  No chemotherapy 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
  Anthracycline only 1.22 (0.79 to 1.86) 1.30 (0.84 to 2.00) 1.49 (0.94 to 2.35) 1.18 (0.77 to 1.82)
  Trastuzumab only —  —  —  — 
  Anthracycline + trastuzumab 8.34 (3.97 to 17 .50) 9.21 (4.35 to 19.54) 9.37 (4.22 to 20.80) 6.23 (2.74 to 14.18)
  Other chemotherapy 1.73 (1.28 to 2.34) 1.81 (1.33 to 2.46) 1.86 (1.31 to 2.64) 1.70 (1.22 to 2.36)
Age ≥75 y 
  No chemotherapy 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
  Anthracycline only 0.76 (0.39 to 1.48) 0.78 (0.40 to 1.53) 0.58 (0.25 to 1.36) 0.79 (0.41 to 1.54)
  Trastuzumab only 2.57 (0.81 to 8.18) 2.76 (0.86 to 8.79) 2.26 (0.55 to 9.31) 3.64 (1.13 to 11.74)
  Anthracycline + trastuzumab  3.54 (0.86 to 14.65) 3.36 (0.81 to 13.94) 3.18 (0.76 to 13.41) 11.30 (2.36 to 54.13)
  Other chemotherapy 1.40 (1.11 to 1.78) 1.44 (1.13 to 1.83) 1.16 (0.85 to 1.57) 1.32 (1.02 to 1.72)
*    Analyses were conducted using multivariable Cox proportional hazards regression to estimate the risk of HF/CM associated with time-varying chemotherapy 
exposures to account for changes in chemotherapy use. Each participant began accruing person-time on the date of chemotherapy initiation (ie, index date) and 
stopped accruing person-time at the time of incident HF/CM diagnosis, health plan disenrollment, death, or December 31, 2009, whichever came first.. All models 
were adjusted for CRN site (eight sites mentioned earlier), age at diagnosis (<55, 55–64, 65–74, ≥75 years), Charlson comorbidity index (0, 1, 2, ≥3), summary 
stage at diagnosis (local vs regional), diagnosis year (categorical for each year), and radiation treatment (yes vs no). The primary analysis (first column and first row) 
included all women; subsequent analyses (following rows) were stratified by age groups (<55, 55–64, 65–74, ≥75 years). Sensitivity analyses were conducted 
in order to address potential limitations and biases in observational administrative data. HF/CM = heart failure and/or cardiomyopathy; HR = hazard ratio; 
CI = confidence interval; — = no HF/CM events occurred among these women.
†    Increased the index date to 234 days after breast cancer diagnosis in unexposed women to exclude any additional possibility of prevalent HF/CM.
‡    Excluded women with comorbidities (ie, women with a Charlson score >1; n = 1854 women).
§    Excluded late chemotherapy initiators, that is, women who initiated chemotherapy more than 12 months after breast cancer diagnosis (n = 519 women).Vol. 104, Issue 17  |  September 5, 2012 1300 Articles | JNCI
practice of additional heart monitoring, and availability of non–
anthracycline-based treatment alternatives.
Observational comparative safety and effectiveness studies 
using administrative data are important to conduct for several rea-
sons. First, the ability to collect automated administrative data on 
a large number of diverse people, as was the case in our study, is 
often a more cost-effective alternative to extensive medical record 
review on a small number of patients. But second, and perhaps even 
more important, observational studies allow for estimation of risks 
and benefits in community practice, which includes patients who 
may not be eligible for clinical trials. Clinical trials may provide 
more relevant estimates for patients who are eligible candidates, 
but many people are not and still receive these treatments in com-
munity practice. Thus, clinical trials may have better internal val-
idity than observational studies because they can reduce bias from 
confounding factors through randomization; however, their exter-
nal validity is often worse because of selection bias and eligibility 
criteria. The opposite is often true for observational studies, with 
better external validity than clinical trials but at the expense of 
internal validity.
Therefore, limitations of observational studies, particularly those 
using administrative data such as ours, cannot be ignored. A primary 
example in our analyses is that our administrative coding algorithm 
for incident HF/CM is prone to misclassification. Our PPV for HF/
Figure 2.  Cumulative incidence of heart failure and/or cardiomyopathy (HF/CM) in women with invasive breast cancer over 5 years by adjuvant 
chemotherapy and age groups. Adjusted cumulative incidence of HF/CM and number of patients at risk by exposure group (anthracycline only, 
trastuzumab only, anthracycline + trastuzumab, other chemotherapy, or none) for the first 5 years of follow-up, by age at diagnosis. Cumulative 
incidence was adjusted for Cancer Research Network (CRN) site (eight sites), age at diagnosis (<55, 55–64, 65–74, ≥75 years), Charlson comorbidity 
index (0, 1, 2, ≥3), summary stage at diagnosis (local vs regional), year of diagnosis (categorical for each year), and radiation treatment (yes vs no). 
A) Age <55 years. B) Age 55–64 years. C) Age 65–74 years. D) Age ≥75 years.JNCI | Articles 1301 jnci.oxfordjournals.org
CM suggests that administrative codes include a substantial percent-
age of false-positive diagnoses, which would result in overestimated 
cumulative HF/CM incidence. For example, our 5-year cumula-
tive incidence of HF/CM among women exposed to anthracycline 
plus trastuzumab may be 13.9%, based on a PPV of 69%, rather 
than 20.1%; it could range from 6.6% to 16.5% if the PPV was 
33% or 82%, respectively. More precise incidence rates would not 
only require validation of outcomes through chart review but also 
improved documentation and surveillance for cardiotoxicity in rou-
tine practice. If diagnostic coding is more common among patients 
after treatment with potentially cardiotoxic agents presumably owing 
to increased surveillance, this may result in overattribution from these 
observational associations. For example, detection bias or misclassifi-
cation may explain the increased HF/CM incidence among women 
receiving trastuzumab alone, although these estimates are based on a 
small sample size. Increased screening for cardiac disease is also likely 
to occur immediately after cancer diagnosis and before initiation of 
chemotherapy, and documentation of cardiac disease in such patients 
will justify the avoidance of potentially cardiotoxic agents. Because 
of these potential detection biases, these population-based incidence 
estimates of cardiotoxicity associated with chemotherapy should be 
interpreted with caution. Even in the presence of false-positive diag-
noses and misclassification, our results suggest a greater risk of HF/
CM than that previously estimated from clinical trials. Our study has 
a few additional limitations. Relying entirely on administrative data 
limited the details of our data collection and, subsequently, the extent 
of our analyses. For example, we had no information on drug dose, 
the types of chemotherapy in the “other chemotherapy” group, LVEF 
measures, and breast cancer recurrence—elements typically meas-
ured and evaluated in clinical trials. For example, LVEF is typically 
ascertained before anthracycline or trastuzumab administration, and 
if reduced, the patient would not be considered eligible for clinical 
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trial enrollment. In real-world practice, the frequency of LVEF test-
ing varied widely across CRN sites, and a sizeable proportion never 
received one of these tests based on a detailed review of the medical 
record (31). If LVEF testing had been routinely used in clinical prac-
tice and available from administrative data, it may have allowed for 
more appropriate comparisons across exposure groups. Further, we 
may have been able to evaluate permanent vs transient HF/CM. HF/
CM following trastuzumab may be reversible with drug discontinu-
ation, whereas HF/CM following anthracycline may be permanent 
(18,40). Accurate administrative data on LVEF testing and results 
would have been necessary to conduct this analysis.
More broadly, selection bias in community-based studies of 
cancer treatment is likely to be prominent and uncontrollable. 
We noted profound differences in age, comorbidities, stage of 
disease, and other factors among women receiving various treat-
ment options. Although our primary analyses attempted to adjust 
for these differences to account for treatment selection biases and 
different cardiovascular risk profiles, residual confounding likely 
still exists, especially among older women. Adjusting for specific 
cardiovascular-related comorbidities, such as hypertension and dia-
betes rather than Charlson comorbidity score, may have reduced 
residual confounding but we did not collect these data at all CRN 
sites. Therefore, our incidence rates may not represent the “truth” 
of community practice; however, they show strong signals for asso-
ciations between anthracycline, trastuzumab, and HF/CM.
In conclusion, we noted increased risks of incident HF/CM 
associated with anthracycline plus trastuzumab administration. 
While risk of anthracycline-associated HF/CM among women 
less than 65 years was similar to results from randomized clinical 
trials, trastuzumab-associated HF/CM risk (whether administered 
alone or following anthracycline) was greater than that previously 
reported. Our results highlight the importance of generalizability 
in applying clinical trial findings to community settings; although 
similar to clinical trial results, these population-based results cannot 
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be attributed to any single patient in clinical practice. The vari-
ability in predictive value of our HF/CM measure is a limitation, 
and studies with detailed data on LVEF measures will be needed 
to confirm our findings. Nevertheless, our study demonstrates the 
added value and potential of observational administrative data to 
complement clinical trials to achieve a more complete picture of 
cancer treatment safety.
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